Lipid Nanoparticles for Ocular Gene Delivery
Open accessThe DOI matches its Crossref record; 97 of the 99 references it cites were found in a registry or an index.
Abstract
Lipids contain hydrocarbons and are the building blocks of cells. Lipids can naturally form themselves into nano-films and nano-structures, micelles, reverse micelles, and liposomes. Micelles or reverse micelles are monolayer structures, whereas liposomes are bilayer structures. Liposomes have been recognized as carriers for drug delivery. Solid lipid nanoparticles and lipoplex (liposome-polycation-DNA complex), also called lipid nanoparticles, are currently used to deliver drugs and genes to ocular tissues. A solid lipid nanoparticle (SLN) is typically spherical, and possesses a solid lipid core matrix that can solubilize lipophilic molecules. The lipid nanoparticle, called the liposome protamine/DNA lipoplex (LPD), is electrostatically assembled from cationic liposomes and an anionic protamine-DNA complex. The LPD nanoparticles contain a highly condensed DNA core surrounded by lipid bilayers. SLNs are extensively used to deliver drugs to the cornea. LPD nanoparticles are used to target the retina. Age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy are the most common retinal diseases in humans. There have also been promising results achieved recently with LPD nanoparticles to deliver functional genes and micro RNA to treat retinal diseases. Here, we review recent advances in ocular drug and gene delivery employing lipid nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Liposomes-protamine-DNA (LPD), in combination with a nuclear localization signal (NLS) peptide and a transactivator of transcription (TAT) peptide, make cell-specific and efficient gene delivery with sustained gene expression [35].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978 · cited 1×
“In the final analysis, liposomes depend on continually improving the formulation of the nanoparticles’ coating and DNA design to increase the transfection efficiency [76,77].”
BackgroundDiffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · cited 1×
“Liposomes were first identified in 1965 [63], and were successfully applied as cationic liposome complexes via intravenous DNA delivery into adult mice in 1993.”
Jain, P. K., Huang, X., El-Sayed, I. H., & El-Sayed, M. A. (2008) · Accounts of Chemical Research · doi:10.1021/ar7002804 · Cited by 4,215 · cited 1×
“Therefore, liposomes are artificial phospholipid bilayers; as a result, liposomes have biocompatible characteristics [49,50].”
BackgroundIn Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,416 · cited 1×
“The TAT-fusions have been shown to cross the blood–brain barrier [81].”
BackgroundSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In clinical trials, three independent groups reported vision improvements upon the viral-mediated delivery of the Rpe65 gene in patients with Rpe65-associated Leber’s congenital amaurosis (LCA) [89–91].”
BackgroundNew-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“In clinical trials, three independent groups reported vision improvements upon the viral-mediated delivery of the Rpe65 gene in patients with Rpe65-associated Leber’s congenital amaurosis (LCA) [89–91].”
BackgroundThe Basic Science of Gene Therapy
Mulligan, R. C. (1993) · Science · doi:10.1126/science.8493530 · Cited by 1,741 · cited 1×
“The success of gene therapy relies on the development of efficient, non-toxic gene carriers that can encapsulate and deliver foreign genetic materials into specific cell types [26].”
BackgroundFutaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., & Sugiura, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007540200 · Cited by 1,662
Green, M., & Loewenstein, P. M. (1988) · Cell · doi:10.1016/0092-8674(88)90262-0 · Cited by 1,553 · cited 1×
“In 1988, the first CPP was sequenced from an HIV-1-encoded cell-penetrating transactivator of transcription (TAT) peptide, and delivered efficiently through cell membranes; TAT has been widely applied since then [83–85].”
Method
Research works printed but not linked: 1
- Immordino, 2006, Stealth liposomes, review of the basic science, rationale, and clinical applications, existing and potential, Int. J. Nanomedicine., 1, 297
Cited by
Solid lipid nanoparticles: a review on recent perspectives and patents
Paliwal, R., Paliwal, S. R., Kenwat, R., Kurmi, B. D., & Sahu, M. K. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1720649 · Cited by 337
“20 Ocular gene delivery Lipid Nanoparticles for Ocular Gene Delivery [47] 21 Topical immunization A highlight on lipid based nanocarriers for transcutaneous immunization [48] 22 Nucleic acid delivery Solid lipid nanoparticles as nucleic acid delivery system: properties and molecular mechanisms [49] 23 Topical delivery…”
BackgroundPrasad, M., Lambe, U. P., Brar, B., Shah, I., J, M., Ranjan, K., Rao, R., Kumar, S., Mahant, S., Khurana, S. K., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.026 · Cited by 327
A review on recent drug delivery systems for posterior segment of eye
Nayak, K., & Misra, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.138 · Cited by 225
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches
Mandal, A., Pal, D., Agrahari, V., Trinh, H. M., Joseph, M., & Mitra, A. K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.008 · Cited by 225
“Both SLNs and NLCs have shown potential in delivering small molecules to ocular tissues [171-173].”
BackgroundNanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez-Gascón, A., Solinís, M. Á., & del Pozo-Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 223
Gene Therapy in Cancer Treatment: Why Go Nano?
Roma-Rodrigues, C., Rivas-García, L., Baptista, P. V., & Fernandes, A. R. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030233 · Cited by 220
“Lipids nanoparticles charged with drugs or a condensed DNA core surrounded by lipid bilayers have been applied in retinitis pigmentosa or age-related macular degeneration [221].”
BackgroundSánchez-López, E., Espina, M., Doktorovova, S., Souto, E. B., & García, M. L. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.10.013 · Cited by 185
Potential applications and human biosafety of nanomaterials used in nanomedicine
Su, H., Wang, Y., Gu, Y., Bowman, L., Zhao, J., & Ding, M. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3476 · Cited by 178
“For example, lipid NPs, called liposome protamine/DNA lipoplex (LPD), are used for ocular gene delivery (Wang et al., 2015b).”
InfluentialSelf-citationChetoni, P., Burgalassi, S., Monti, D., Tampucci, S., Tullio, V., Cuffini, A. M., Muntoni, E., Spagnolo, R., Zara, G. P., & Cavalli, R. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.10.006 · Cited by 152
“Even if in the last ten years SLN have been studied extensively and several manuscripts reported the advantage obtained by their use as delivery systems for many ophthalmic drugs (antiinflamatory, antiglaucoma, antiibacterial, antifungal), natural extracts, antioxidant molecules and gene therapy [9, 20, 21, 30-35], in…”
BackgroundRelevance of Lipid-Based Products in the Management of Dry Eye Disease
Garrigue, J., Amrane, M., Faure, M.-O., Holopainen, J. M., & Tong, L. H. T. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0052 · Cited by 147
Mohammed, H. A., Khan, R. A., Singh, V., Yusuf, M., Akhtar, N., Sulaiman, G. M., Albukhaty, S., Abdellatif, A. A. H., Khan, M., Mohammed, S. A. A., et al. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2022-0517 · Cited by 125
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120
Liposomal delivery of CRISPR/Cas9
Zhen, S., & Li, X. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0141-7 · Cited by 114
A new developing class of gene delivery: messenger RNA-based therapeutics
Meng, Z., O'Keeffe-Ahern, J., Lyu, J., Pierucci, L., Zhou, D., & Wang, W. (2017) · Biomaterials Science · doi:10.1039/c7bm00712d · Cited by 86
Non-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80
“37 Lipid-based ocular delivery has been reviewed recently in [59] and examples include lipid-based gene delivery to ocular tissues alone [60] or in combination with polymers [61].”
BackgroundKumar, A., Roy, S., Srivastava, A., Naikwade, M. M., Purohit, B., Mahato, K., Naidu, V. G. M., & Chandra, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818823-1.00010-7 · Cited by 72
mRNA-based therapeutics–Advances and perspectives
Sergeeva, O. V., Koteliansky, V. E., & Zatsepin, T. S. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070075 · Cited by 71
Patil, A., Lakhani, P., Taskar, P., Wu, K.-W., Sweeney, C., Avula, B., Wang, Y.-H., Khan, I. A., & Majumdar, S. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.04.014 · Cited by 71
Self-citationWan, C.-R., Muya, L. W., Kansara, V. S., & Ciulla, T. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020288 · Cited by 69
Colloidal nanosystems with mucoadhesive properties designed for ocular topical delivery
Silva, B., Bráz, B. S., Delgado, E., & Gonçalves, L. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120873 · Cited by 67
The Application of Nanoparticles in Diagnosis and Treatment of Kidney Diseases
Paluszkiewicz, P., Martuszewski, A., Zaręba, N., Wala, K., Banasik, M., & Kepinská, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010131 · Cited by 60
“Their effectiveness has been proven, among others in oncology, ophthalmology and in the treatment of cystic fibrosis [77,78].”
BackgroundNanotechnology in regenerative ophthalmology
Sahle, F. F., Kim, S., Niloy, K. K., Tahia, F., Fili, C. V., Cooper, E., Hamilton, D. J., & Lowe, T. L. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.10.006 · Cited by 59
Wang, Y., Rajala, A., Cao, B., Ranjo-Bishop, M., Agbaga, M.-P., Mao, C., & Rajala, R. V. S. (2016) · Theranostics · doi:10.7150/thno.15230 · Cited by 52
“One of the limitations of LPD is cell specificity [7].”
BackgroundSelf-citationRen, D., Fisson, S., Dalkara, D., & Ail, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091973 · Cited by 52
“Even though one of the early motivations for developing non-viral vectors was to avoid viral components to have lower immunogenicity [78,79], these studies highlight that depending on the non-viral vectors used, the immune consequence could be severe, as is in the case of chitosan, or could be protective, as shown by…”
BackgroundNon-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
Ocular drug delivery: advancements and innovations
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091931 · Cited by 50
Toward Gene Transfer Nanoparticles as Therapeutics
Kavanagh, E. W., & Green, J. J. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102145 · Cited by 48
da Ana, R., Fonseca, J., Karczewski, J., Silva, A. M., Zielińska, A., & Souto, E. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012102 · Cited by 38
“Liposomes can also entrap and protect drugs on the journey to the target site [18].”
BackgroundMarslin, G., Siram, K., Liu, X., Khandelwal, V. K. M., Shen, X., Wang, X., & Franklin, G. (2017) · Molecules · doi:10.3390/molecules22112040 · Cited by 34
“SLNs are colloidal carriers with a solid lipid matrix that can solubilize lipophilic molecules and usually stabilized by surfactants [14,15].”
BackgroundFuglestad, B., Gupta, K., Wand, A. J., & Sharp, K. A. (2016) · Langmuir · doi:10.1021/acs.langmuir.5b03981 · Cited by 33
Abedi, E., Akhavan, H., Mohammadi, H., & Banasaz, S. (2023) · Food Control · doi:10.1016/j.foodcont.2023.110237 · Cited by 35
Role of small interfering RNA (siRNA) in targeting ocular neovascularization: A review
Supe, S., Upadhya, A., & Singh, K. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108329 · Cited by 31
Nanotheranostics Revolutionizing Gene Therapy: Emerging Applications in Gene Delivery Enhancement
Guzmán-Sastoque, P., Rodríguez, C. F., Monsalve, M. C., Castellanos, S., Manrique-Moreno, A., Reyes, L. H., & Cruz, J. C. (2025) · Journal of Nanotheranostics · doi:10.3390/jnt6020010 · Cited by 32
Nanotechnology for Age-Related Macular Degeneration
Yang, B. X., Li, G., Liu, J., Li, X., Zhang, S., Sun, F., & Liu, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122035 · Cited by 32
The Ocular Gene Delivery Landscape
Sahu, B., Chug, I., & Khanna, H. (2021) · Biomolecules · doi:10.3390/biom11081135 · Cited by 28
“Liposomes-protamine-DNA (LPD), in combination with a nuclear localization signal (NLS) peptide and a transactivator of transcription (TAT) peptide, make cell-specific and efficient gene delivery with sustained gene expression [35].”
BackgroundSuprachoroidal delivery enables targeting, localization and durability of small molecule suspensions
Kansara, V. S., Hancock, S. E., Muya, L. W., & Ciulla, T. A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.061 · Cited by 27
Wu, M., Xiong, H., Zou, H., Li, M., Li, P., Zhou, Y., Xu, Y., Jia, J., Liu, F., Zhao, H., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.02.006 · Cited by 26
mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Vicente-Pascual, M., Rodríguez‐Gascón, A., Garelli, S., Battaglia, L., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091472 · Cited by 25
Lipid-based nanocarriers for ocular drug delivery
Farid, R. M., El-Salamouni, N. S., El-Kamel, A. H., & El-Gamal, S. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46143-6.00016-6 · Cited by 23
Gene therapy for age-related macular degeneration: a promising frontier in vision preservation
Hushmandi, K., Lam, H. Y., Wong, W., Tan, W., Daryabari, S., Reiter, R. J., Farahani, N., & Kumar, A. P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02246-4 · Cited by 26
“These findings highlight the potential of LNPs to address retinal disorders and other posterior ocular conditions [140, 141].”
Lipid nanoparticles for gene therapy in ocular diseases
González, C. C., Saráoz, J. V. M., Roacho-Pérez, J. A., & Olivas-Armendáriz, I. (2023) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-023-00455-1 · Cited by 22
“However, one of the biggest challenges is to deal with the issue of the back of the eye, because the routes of administration for this section of the eye, specifically periocular and intravitreal, have the ocular barriers as a major impediment [17, 18].”
BackgroundGenetic transformation of fungi
He, L., Feng, J., Lu, S., Chen, Z., Chen, C., He, Y., Yi, X., & Xi, L. (2016) · The International Journal of Developmental Biology · doi:10.1387/ijdb.160026lh · Cited by 20
Cheng, Z., Li, Y., Wang, K., Zhu, X., Tharkar, P., Shu, W., Zhang, T., Zeng, S., Zhu, L., Murray, M. T., et al. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108906 · Cited by 20
Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
da Ana, R., Gliszczyńska, A., Sánchez‐López, E., García, M. L., Krambeck, K., Kovačević, A. B., & Souto, E. B. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040635 · Cited by 24
Polyol-modified deformable liposomes fortified contact lenses for improved ocular permeability
Dave, J., Jani, H., Patel, Y., Mohite, P. B., Puri, A. V., Chidrawar, V. R., Datta, D., Bandi, S. P., Ranch, K. M., & Singh, S. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2463867 · Cited by 16
Melgar-Asensio, I., Kandela, I. K., Aird, F., Darjatmoko, S. R., Ríos, C. D. L., Sorenson, C. M., Albert, D. M., Sheibani, N., & Henkin, J. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24087 · Cited by 16
“MP and NP, comprising liposome or micellar structures, have also been utilized, including for gene therapy.(28) Manufacturing lipid NP is problematic because of their high affinity for endotoxin,(29) inserted in their structure, and the finding that tissue contacting vitreous is exceptionally TABLE 2.”
MethodRibeiro, M. C. S., de Miranda, M. C., Cunha, P. D. S., Andrade, G. F., Fulgêncio, G. D. O., Gomes, D. A., Fialho, S. L., Pittella, F., Charrueau, C., Escriou, V., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060845 · Cited by 20
Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies
Panikker, P., Roy, S., Ghosh, A., Poornachandra, B., & Ghosh, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906482 · Cited by 19
“Emerging non-viral technologies through chemical methods include synthetic polymers (163) and nanoparticles (NP) (164), physical particles, lipid-based delivery systems (165, 166), and functionalized cell-penetrating peptides (162).”
BackgroundOphthalmic nano-bioconjugates: Critical Challenges and Technological Advances
Sanap, S. N., Bisen, A. C., Agrawal, S., Kedar, A. S., & Bhatta, R. S. (2023) · Therapeutic Delivery · doi:10.4155/tde-2023-0031 · Cited by 16
How Lipid Cores Affect Lipid Nanoparticles as Drug and Gene Delivery Systems
Radaic, A., Barbosa, L. R. S., Jaime, C., Kapila, Y. L., Pessine, F. B. T., & de Jesus, M. B. (2016) · Advances in biomembranes and lipid self-assembly · doi:10.1016/bs.abl.2016.04.001 · Cited by 15
The development of highly dense highly protected surfactant ionizable lipid RNA loaded nanoparticles
González-Rioja, R., Salazar, V. A., Bastús, N. G., & Puntes, V. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129296 · Cited by 14
Nano-enhanced Optical Gene Delivery to Retinal Degenerated Mice
Batabyal, S., Gajjeraman, S., Bhattacharya, S., Wright, W. W., & Mohanty, S. K. (2019) · Current Gene Therapy · doi:10.2174/1566523219666191017114044 · Cited by 14
Development and applications of lipid hydrophilic headgroups for nucleic acid therapy
Ma, W., Fu, X., Zhao, T., Qi, Y., Zhang, S., & Zhao, Y. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108395 · Cited by 13
Ophthalmic dosage forms for drug delivery to posterior segment
Lee, J., & Rhee, Y.-S. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00554-8 · Cited by 14
Essential cues of engineered polymeric materials regulating gene transfer pathways
Islam, M. A., Park, T., Firdous, J., Li, H.-S., Jiménez-Pérez, Z. E., Lim, M., Choi, J.-W., Yun, C., & Cho, C. (2022) · Progress in Materials Science · doi:10.1016/j.pmatsci.2022.100961 · Cited by 12
Nanoparticles as Delivery Vehicles for the Treatment of Retinal Degenerative Diseases
Wang, Y., Rajala, A., & Rajala, R. V. S. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-75402-4_15 · Cited by 12
“LPD nanoparticles are electrostatically assembled from cationic liposomes and an anionic protamine-DNA complex with two peptides NLS (nuclear localization peptide) and TAT (transactivator of transcription), thereby peptide-modified LPD reach optimal transfer efficiency (Ma et al., 2013; Rajala et al., 2014; Wang et al…”
BackgroundSelf-citationNon-Viral Delivery Systems to Transport Nucleic Acids for Inherited Retinal Disorders
Jony, M. J. H., Joshi, A., Dash, A. K., & Shukla, S. (2025) · Pharmaceuticals · doi:10.3390/ph18010087 · Cited by 12
Combes, R. D., & Shah, A. B. (2016) · Alternatives to Laboratory Animals · doi:10.1177/026119291604400302 · Cited by 14
Sultana, S., Yusuf, M., & Sharma, V. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03159-8 · Cited by 12
“These lipid-based nanoparticles protect genetic material from degradation, enhance cellular uptake, and allow for targeted delivery to the retinal pigment epithelium or photoreceptors [285, 286].”
Plasmid-DNA lipid nanovaccines
García‐Rendón, A., Garibay‐Escobar, A., Guzman, R. Z., & Tejeda‐Mansir, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813687-4.00006-2 · Cited by 9
Wang, B., Lu, J., Zhang, X., Hu, R., & Ma, H. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1669104 · Cited by 13
“Their needle-like ends were capable of penetrating bacterial membranes, which substantially increased their antibacterial performance against S. aureus by causing direct structural disruption of the cell wall (Lin and Wang, 2015).”
Chirco, K. R., Martinez, C., & Lamba, D. A. (2023) · Vision Research · doi:10.1016/j.visres.2023.108257 · Cited by 10
Yamada, A., Mitsueda, A., Hasan, M., Ueda, M., Hama, S., Warashina, S., Nakamura, T., Harashima, H., & Kogure, K. (2015) · Biomaterials Science · doi:10.1039/c5bm00327j · Cited by 8
Application of Nanomaterials in the Diagnosis and Treatment of Retinal Diseases
Yao, Y., Cao, Q., Fang, H., & Tian, H. (2025) · Small · doi:10.1002/smll.202503070 · Cited by 7
Zeng, L., Wei, Y., Qiu, Y., Bi, R., Peng, H., Hu, B., & Li, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s521960 · Cited by 9
“145,146 Additionally, cationic liposomes interacting with a high proportion of dendritic cells enhanced intracellular localization and improved targeting efficiency.”
Diress, M., Ionescu, C. M., Foster, T., Lim, P., Sen, L. Y., Kovačević, B., Wagle, S. R., Mooranian, A., & Al‐Salami, H. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107172 · Cited by 5
Advances in Magnetic Nanoparticle-Driven Delivery of Gene Therapies towards Prostate Cancer
Panday, R., Abdalla, A. M. E., Neupane, M., Khadka, S., Kricha, A., & Yang, G. (2021) · Journal of Nanomaterials · doi:10.1155/2021/6050795 · Cited by 6
New Combination/Application of Polymer-Based Nanoparticles for Biomedical Engineering
Chang, R., Wang, P., & Tseng, C. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0950-2_14 · Cited by 4
Singh, M., Singh, S., Sharma, P., Bhandari, R., Sharma, N., Rajput, R., Gupta, V., Singh, S. K., Dua, K., Chitranshi, N., et al. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107506 · Cited by 4
The Contribution of Nanomedicine in Ocular Oncology
Spyratou, E., Margarita, T., Droulias, A., Zachou, M.-E., & EFSTATHOPOULOS, E. P. (2025) · Cancers · doi:10.3390/cancers17071186 · Cited by 4
“Despite their promise, these drawbacks necessitate careful consideration when using viral vectors in gene therapy and highlight the need for safer alternatives [113–115].”
Paoletti, L., Clerck, K. D., Coster, E. D., Matricardi, P., Remaut, K., & Peynshaert, K. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01921-w · Cited by 4
“In fact, viral vectors, relying on the natural ability of viruses to infect human cells, and non-viral ones, using different chemical and physical methods to deliver therapeutic genetic material, provide the organ - ism with the right tools to restore the altered functionalities [ 13–15].”
Solid lipid nanoparticles in photodynamic therapy
Barbosa, H. F. G., & Tedesco, A. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85595-2.00013-x · Cited by 3
Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., Ruiz, A. I., & Solinís, M. Á. (2016) · Wiley eBooks · doi:10.1002/9780470015902.a0024274 · Cited by 5
Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma
Azani, A., Ghassemifar, V., Mehrdad, Z., Saberivand, M., Pour, A. B., Tahmasebi, S., Gharedaghi, H., Sharafi, M., Foroozand, H., Meigoli, M. S. S., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70425 · Cited by 2
“Lipid-based delivery systems [214, 215], polymers [216], physical particles [217], and functionalized cell-penetrating peptides are the chemical delivery meth-ods that have been studied the most.”
Development and characterization of a first-in-class adjustable-dose gene therapy system
Goraltchouk, A., Lourie, J., Hollander, J. M., Rosen, H. G., Fujishiro, A. A., Luppino, F., Zou, K., & Seregin, A. (2024) · Gene · doi:10.1016/j.gene.2024.148500 · Cited by 3
Recapitulation of Cancer Nanotherapeutics
Morani, D. O., Patil, P., & Jain, A. (2021) · Current Nanomedicine · doi:10.2174/2468187311666210121143501 · Cited by 3
Nanocarriers for Vaccine and Gene Delivery Application
Şenel, B., & Büyükköroğlu, G. (2018) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-4781-5.ch014 · Cited by 3
Use of nanoscale-delivery systems in tissue/organ regeneration
Fathi‐Achachelouei, M., Keskin, D. S., & Tezcaner, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102906-0.00026-x · Cited by 2
Nanoparticle Products for the Eye: Preformulation, Formulation, and Manufacturing Considerations
Sánchez‐López, E., Souto, E. B., Espina, M., Cano, A. C., Ettcheto, M., Camins, A., & García, M. L. (2021) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-76367-1_15 · Cited by 2
Huang, B., Xu, W., Qiu, X., Ye, B., Wan, Z., Luo, X., Feng, B., Xiang, S., Nan, K., & Lin, S. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124252 · Cited by 1
A Review of Personalised Molecular Medicine for the Treatment of Corneal Disorders
Courtney, D. G., Thakur, A., Ma, N., Moore, J. E., & Moore, T. (2015) · International Journal of Ophthalmology & Eye Science · doi:10.19070/2332-290x-si02002 · Cited by 1
Rajala, R. V. S. (2019) · PubMed · Cited by 1
Self-citationCésar, A. L. A., Navarro, L. C., Silva, A. D. M., Castilho, R. O., Goulart, G. A. C., Heida, G. F., Ferreira, A. J., Cronemberger, S., & Faraco, A. A. G. (2020) · Revista de ciencias farmaceuticas · doi:10.4322/2179-443x.0636 · Cited by 1
Koduru, R. K., Kasaraneni, J., & Juturi, R. K. R. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i40a32226 · Cited by 1
Double Emulsion Mucoadhesive Nanoparticles for Hydrophilic Ocular Drug Delivery
Bahsoun, N. E.-H. (2018) · UWSpace (University of Waterloo) · Cited by 1
Development of plasmid DNA nanoparticles for mitochondrial gene therapy
Costa, D. R. B., de Sousa, F. P., & Queiroz, J. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818435-6.00011-6
Role of Nanotechnology in Combatting Disease and Disorders of Ophthalmology
Sharon, M. (2022) · Wiley eBooks · doi:10.1002/9781119764205.ch9
Nanomaterials for Gene Therapy
Karthik, V., Arumugam, V., Raj, D. D. D., Nagarjun, T. G. N., Poornima, S., Subbaiya, R., & Saravanan, M. (2022) · Wiley eBooks · doi:10.1002/9781119558026.ch6
Nanoparticles in Ophthalmology
(2022) · Journal of Ophthalmology & Clinical Research · doi:10.33140/jocr.06.03.01
Role of Magnetic Nanomaterials in Biosafety and Bioregulation Facets
Kusuma, H. S., Ukhurebor, K. E., Aigbe, U. O., Onyancha, R. B., Onyeachu, I. B., & Darmokoesoemo, H. (2023) · Engineering materials · doi:10.1007/978-3-031-36088-6_11 · Cited by 1
Wu, G., Wang, S., Chen, Z., Li, J., & Li, K. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1890483
Retinitis Pigmentosa: A Review of Its Pathogenesis and Emerging Molecular and Cellular Therapies
Tuli, N., Baeshen, M., Echbicheb, M., Kulbay, M., Ayalon, A., Ali, S. K., & Qian, C. X. (2026) · Vision · doi:10.3390/vision10040083
“They are highly bio-https compatible, and their properties can be manipulated to improve targeted delivery to retinal cells [305,331,332].”
Metadata
- Authors
- Wang, Y., Rajala, A., & Rajala, R.
- Affiliations
- Dean McGee Eye Institute (US)
- Corresponding author
- Rajala, Raju
- Venue
- Journal of Functional Biomaterials
- Publisher
- MDPI AG
- Published
- 2015-06-08
- Volume
- 6
- Issue
- 2
- Pages
- 379-394
- ISSN
- 2079-4983 (ISSN-L)
- PMC
- PMC4493518
- OpenAlex
- W1506466933
- Cited by
- 93
- References
- 99
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 2 · 2023: 9 · 2022: 12 · 2021: 12 · 2020: 6 · 2019: 7 · 2018: 10 · 2017: 7 · 2016: 9 · 2015: 3
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Functional Biomaterials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- NIH (EY016507, EY00871, EY021725)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- lipid nanoparticles, ocular gene delivery, solid lipid nanoparticles, lipoplexes, liposomes, corneal drug delivery, retinal gene therapy, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, microRNA delivery, retinal disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.